TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18420099
Drug: Niacin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (titrated to 2 g/day)
Study: 18420099
Drug: Ezetimibe/Simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin (10/20 mg/day)
Study: 10837304
Drug: [57Fe]ferrous fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: [57Fe]ferrous fumarate with 25 mg ascorbic acid
Study: 10837304
Drug: [57Fe]ferrous fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: [57Fe]ferrous fumarate with 50 mg ascorbic acid
Study: 8463920
Drug: Herbal tea
Normalized name: Senna Oral Powder for Suspension [CORRECTOL HERBAL TEA LAXATIVE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal tea preparation
Study: 2566321
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg)
Study: 10806134
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg)
Study: 27899107
Drug: Unplugged program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unplugged program (12 weekly classes)
Study: 3565796
Drug: Aminophylline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (2 mg/kg)
Study: 3565796
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline (5 ml) - Control
Study: 23982026
Drug: Light sedation
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light sedation (1.26 ± 0.35 μg/mL)
Study: 23982026
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation (2.52 ± 0.71 μg/mL)
Study: 15910382
Drug: Intravenous cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclosporine (CYS)
Study: 16385545
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg once daily
Study: 10555907
Drug: Rofecoxib 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 125 mg once daily
Study: 25880964
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (people who inject drugs)
Study: 23323566
Drug: Gastric contraction
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric contraction modulation treatment (TANTALUS-DIAMOND)
Study: 15356042
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg) once daily for 6 months
Study: 17543413
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 6 months
Study: 2530191
Drug: Doxycycline 50
Normalized name: doxycycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 50 mg daily
Study: 2530191
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg daily (50 mg twice daily)
Study: 22562960
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g testosterone gel daily for 6 months
Study: 11412291
Drug: Propofol 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3.5 mg kg(‐1)
Study: 12631047
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg kg(‐1)
Study: 12631047
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg(‐1)
Study: 9180665
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 2.5 mg qd (increased to 5 mg qd after 3 weeks and to 10 mg qd after 6 weeks if SDBP > 90 mm Hg)
Study: 1609548
Drug: DTP-PRP/D vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-PRP/D vaccine (109 children)
Study: 1609548
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine (66 children)
Study: 4027146
Drug: Nicardipine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (5-20 mg three times daily)
Study: 4027146
Drug: Nicardipine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine and Atenolol combination
Study: 31972657
Drug: Remimazolam continuous
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam continuous IV infusion
Study: 29803816
Drug: Individual medical
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual medical nutrition therapy (MNT)
Study: 19573262
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (Control)
Study: 20418403
Drug: Beliefs about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs about the influenza vaccine
Study: 18041735
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg daily for 10 days with amprenavir 600 mg twice daily added at day 11
Study: 16025964
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (western medicine plus double faced blue treatment)
Study: 10799372
Drug: High-dose BCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BCS (approximately 45 g)
Study: 10799372
Drug: Low-dose BCS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BCS (approximately 25 g)
Study: 8625493
Drug: Diet C
Normalized name: Diet Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet C (12 day dietary supplement to the standard diet of 500 g/day broccoli)
Study: 1453032
Drug: Metronidazole (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1000 mg)
Study: 3894277
Drug: Mitoxantrone (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (14 mg/m2)
Study: 3894277
Drug: Bisantrene (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisantrene (260 mg/m2)
Study: 28181386
Drug: In-home rehabilitation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home rehabilitation (physical treatment program once a week and basic nursing care)
Study: 21790771
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with xylazine (0.5 mg/kg bwt, iv)
Study: 11237056
Drug: Idarubicin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin (12 mg/m2/day for 3 days)
Study: 11237056
Drug: Daunorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (60 mg/m2/day for 3 days)
Study: 9552042
Drug: CC arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC arm (Carboplatin and Cisplatin)
Study: 3286068
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 1 g, 3 times daily for 10 days
Study: 29875024
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (GDT) guided by esophageal Doppler monitoring
Study: 21770897
Drug: L-carnitine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (0.05 g/kg) administered with a rapid infusion diluted in 250 ml of saline solution
Study: 16980000
Drug: High-dose TMP/SXT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TMP/SXT (320/1600 mg, daily in two divided doses)
Study: 16980000
Drug: Low to
Normalized name: Mutton Tallow Topical application Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low to moderate doses of TMP/SXT (either 80/400 mg or 160/800 mg, daily)
Study: 15250200
Drug: Nitrate ester
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate ester preparation
Study: 11059223
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with V.D3 and etidronate (group B)
Study: 11059223
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with active vitamin D3 (group A)
Study: 8418608
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/kg per day administered in three divided doses)
Study: 3614304
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate (500 mg)
Study: 3614304
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate (500 mg)
Study: 3614304
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate (500 mg)
Study: 18553042
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (500 mg)
Study: 3614304
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (500 mg)
Study: 22995802
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg daily (A)
Study: 22995802
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg daily (V)
Study: 22995802
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg + Valsartan 160 mg daily (A+V)
Study: 19080096
Drug: BIS monitoring
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS monitoring during intravenous anesthesia with remifentanil and propofol
Study: 9068739
Drug: erythromycin 4%/zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythromycin 4%/zinc 1.2% solution
Study: 3535492
Drug: Oral capsules
Normalized name: Plenity Oral Capsules
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules of potassium metabisulfite
Study: 3535492
Drug: Double-blind rechallenge
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind rechallenge with metabisulfite capsules
Study: 9246276
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol anaesthesia
Study: 19783710
Drug: Sitagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 200 mg/d for 11 days + Warfarin 30 mg on day 5
Study: 19783710
Drug: Warfarin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 30 mg alone on day 1
Study: 17357336
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg 'on-demand'
Study: 8943962
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg daily
Study: 17357336
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg in four-week courses during a relapse
Study: 12727707
Drug: DHA, 2
Normalized name: Prenatal DHA, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA, 2 g/day for 6 weeks
Study: 8842054
Drug: Nadolol 160mg
Normalized name: NADOLOL 160MG TAB
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol 160mg tablet (Zenith‐Goldline Pharmaceuticals)
Study: 8842054
Drug: Nadolol 40mg
Normalized name: NADOLOL 40MG TAB
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol 40mg tablet (Zenith‐Goldline Pharmaceuticals)
Study: 8842054
Drug: Nadolol 40mg
Normalized name: NADOLOL 40MG TAB
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol 40mg tablet (80mg dose)
Study: 22926607
Drug: oral CYT
Normalized name: CYT-6091
DrugBank: CYT-6091 (DB05991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral CYT + O3FA (2 g O3FA twice a day, 1 g CYT twice a day)
Study: 22926607
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + O3FA (2 g O3FA twice a day)
Study: 18796095
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a (40KD) plus ribavirin (1,000/1,200 mg/day)
Study: 15654292
Drug: Mecamylamine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (7.5 mg)
Study: 15201697
Drug: Diazoxide (DZX)
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazoxide (DZX) 1.5 mg/kg infused intravenously in 5 min followed by a 5‐min washout before cardiopulmonary bypass.
Study: 15201697
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received placebo infusion.
Study: 11102590
Drug: Testosterone implants
Normalized name: testosterone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone implants (800-1200 mg every 3 months)
Study: 11102590
Drug: Testosterone implants
Normalized name: testosterone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone implants (800 mg) with finasteride (5alpha-reductase inhibitor)
Study: 8165591
Drug: Isotretinoin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (40 mg) administered in the morning and evening for 5 days
Study: 16815137
Drug: 100/50 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/50 microg of fluticasone propionate/salmeterol administered through a Diskus inhaler twice daily for 24 weeks
Study: 16815137
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg of fluticasone propionate administered through a Diskus inhaler twice daily for 24 weeks
Study: 9103129
Drug: Propafenone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (500 mg oral dose)
Study: 3542826
Drug: Isotonic amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic amino acid solution
Study: 12622501
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg disintegrating tablets, administered orally every 12 hours for 3 days
Study: 12622501
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally every 12 hours for 3 days
Study: 10374221
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment
Study: 22929568
Drug: standard abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard abciximab infusion (A)
Study: 22929568
Drug: thrombectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thrombectomy followed by abciximab infusion with the ClearWay catheter (T+C)
Study: 18720328
Drug: Betahistine 3x12
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 3x12 mg
Study: 17361524
Drug: Chibixiao Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chibixiao Recipe (CBX) in combination with minocycline and spironolactone
Study: 8910149
Drug: Albunex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex (2 to 8 mL injected before and after coronary revascularization)
Study: 1725447
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg p.o. once daily
Study: 6617205
Drug: i.m. norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. norethisterone enanthate (NET‐e) 200 mg every two months
Study: 6617205
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination of 1-norgestrel 150 micrograms and ethinyl estradiol 30 micrograms
Study: 26674292
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment (procedures and drinking cure)
Study: 24703722
Drug: Itolizumab arm
Normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Itolizumab arm A (4-week loading dose of 0.4 mg/kg/wk followed by 1.6 mg/kg every 2 weeks)
Study: 24703722
Drug: Itolizumab arm
Normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Itolizumab arm B (1.6 mg/kg every 2 weeks)
Study: 24703722
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (A, B, placebo)
Study: 19775046
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/kg (Group IB)
Study: 9517944
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg every 12 h)
Study: 16892732
Drug: Prednisolone (30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30mg once daily in the morning)
Study: 16892732
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (600-800mg per day in b.i.d. dosage)
Study: 2195106
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain enriched amino acid mixture (1 g/kg per day)
Study: 2195106
Drug: Isocaloric glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric glucose infusion
Study: 7377640
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline tablets
Study: 7377640
Drug: Short acting
Normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short acting theophylline tablets
Study: 15347709
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (control)
Study: 15871754
Drug: Noninvasive positive-pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive positive-pressure ventilation (NPPV) daily for 3 days for intervals of 8, 6, and 4 hours, plus standard therapy
Study: 10487134
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium (Group I)
Study: 10487134
Drug: 0.015 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015 mg/kg pancuronium (Group II)
Study: 10487134
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg rocuronium (Group III)
Study: 18642635
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CIMT)
Study: 23265995
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g three times daily for 7 days)
Study: 19318384
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (target blood glucose range of 81 to 108 mg/dL)
Study: 19318384
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose control (target blood glucose of 180 mg/dL or less)
Study: 15270803
Drug: Pulsed-dose electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed-dose electrical stimulation (50 micro amps) through silver-plated nylon-dacron stocking electrodes for 8 hours a night for 6 weeks
Study: 11772239
Drug: Novel treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatments targeting specific steps in the disease process, including mycophenolate mofetil and adenosine analogues.
Study: 11772239
Drug: Immunoablative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoablative chemotherapy with or without haematopoietic stem cell rescue.
Study: 11772239
Drug: Blocking co-stimulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking co-stimulatory molecules (e.g., CD40 ligand, CTLA4-Ig).
Study: 29245244
Drug: Joint mobilization
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint mobilization manipulation treatment once a day and regular training twice a day for a month
Study: 8513655
Drug: Naringin solution
Normalized name: Naringin
DrugBank: Naringin (DB16859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringin solution
Study: 3318546
Drug: Etomidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.3 mg/kg)
Study: 20829648
Drug: Imagery Rehearsal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Rehearsal Therapy (IRT)
Study: 23725518
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg/day for 6 months
Study: 16184258
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg
Study: 17000360
Drug: Adenosine (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (0.14 mg/kg/min continuous infusion over 2 minutes)
Study: 26176644
Drug: Both adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both adalimumab preparations
Study: 21718265
Drug: Once-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly resistance training
Study: 12117873
Drug: Polymeric enteral
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric enteral diet (PEN1) containing 35 g of lipids per 1000 kcal, high in oleate (79%) and low in linoleate (6.5%)
Study: 2752179
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1 mg/kg/day)
Study: 2109766
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy on urinary incontinence
Study: 11500583
Drug: Intravenous ajmaline
Normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ajmaline
Study: 12022585
Drug: Amiodarone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone therapy
Study: 14534370
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root (1 g)
Study: 11761012
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole for 7 days
Study: 10972172
Drug: No omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No omeprazole treatment (Control)